175 related articles for article (PubMed ID: 33042819)
1. Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible.
Vucinic V; Jentzsch M; Schwind S; Bach E; Leiblein S; Remane Y; Rieprecht S; Otto S; Kubasch AS; Behre G; Cross M; Platzbecker U; Franke GN
Front Oncol; 2020; 10():1746. PubMed ID: 33042819
[TBL] [Abstract][Full Text] [Related]
2. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
[TBL] [Abstract][Full Text] [Related]
3. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.
Chen EC; Fathi AT; Brunner AM
Onco Targets Ther; 2018; 11():3425-3434. PubMed ID: 29928134
[TBL] [Abstract][Full Text] [Related]
4. CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.
Cafaro A; Giannini MB; Silimbani P; Cangini D; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):455-466. PubMed ID: 32955826
[TBL] [Abstract][Full Text] [Related]
5. Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes.
Jensen IS; Wu E; Sacks NC; Cyr PL; Chung KC
Am Health Drug Benefits; 2018 Oct; 11(7):380-386. PubMed ID: 30647825
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic stem cell transplant overcomes poor prognosis of acute myeloid leukemia with myelodysplasia-related changes.
Ikegawa S; Doki N; Kurosawa S; Yamaguchi T; Sakaguchi M; Harada K; Yamamoto K; Hino Y; Shingai N; Senoo Y; Watanabe K; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
Leuk Lymphoma; 2016; 57(1):76-80. PubMed ID: 26084204
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.
Kobos R; Steinherz PG; Kernan NA; Prockop SE; Scaradavou A; Small TN; Shukla N; Khalaf R; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2012 Mar; 18(3):473-80. PubMed ID: 22079789
[TBL] [Abstract][Full Text] [Related]
8. CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML.
Molica M; Perrone S; Mazzone C; Cesini L; Canichella M; de Fabritiis P
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740508
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia.
Ciftciler R; Demiroglu H; Buyukasık Y; Aladag E; Aksu S; Haznedaroglu IC; Sayınalp N; Ozcebe O; Malkan UY; Goker H
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):177-182. PubMed ID: 30616990
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Hospital Length of Stay and Supportive Care Utilization Between Patients Treated with CPX-351 and 7+3 for Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.
Price K; Cao Z; Lipkin C; Profant D; Robinson S
Clinicoecon Outcomes Res; 2022; 14():21-34. PubMed ID: 35035224
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapies for AML with myelodysplasia-related changes: slowly but surely moving the needle.
Phillips DF; Zeidner JF
Expert Opin Emerg Drugs; 2021 Sep; 26(3):245-257. PubMed ID: 34227451
[No Abstract] [Full Text] [Related]
12. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.
Lin TL; Rizzieri DA; Ryan DH; Schiller GJ; Kolitz JE; Uy GL; Hogge DE; Solomon SR; Wieduwilt MJ; Ryan RJ; Faderl S; Cortes JE; Lancet JE
Blood Adv; 2021 Mar; 5(6):1719-1728. PubMed ID: 33724305
[TBL] [Abstract][Full Text] [Related]
13. CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia.
Lee D; Jain AG; Deutsch Y; Eatrides J; Chan O; Padron E; Kuykendall A; Komrokji R; Lancet J; Sallman D; Talati C; Sweet K
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):774-779. PubMed ID: 35760672
[TBL] [Abstract][Full Text] [Related]
14. [Clinical observation of 12 patients with refractory/relapsed acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation containing cladribine regimen].
Ai H; Fu YW; Wang YQ; Wei XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):827-830. PubMed ID: 31775481
[No Abstract] [Full Text] [Related]
15. Challenges in the diagnosis and treatment of secondary acute myeloid leukemia.
Ossenkoppele G; Montesinos P
Crit Rev Oncol Hematol; 2019 Jun; 138():6-13. PubMed ID: 31092386
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia.
Muto T; Takeuchi M; Yamazaki A; Sugita Y; Tsukamoto S; Sakai S; Takeda Y; Mimura N; Ohwada C; Sakaida E; Aotsuka N; Iseki T; Nakaseko C
Int J Hematol; 2015 Jul; 102(1):86-92. PubMed ID: 25758097
[TBL] [Abstract][Full Text] [Related]
17. AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances.
Koenig KL; Sahasrabudhe KD; Sigmund AM; Bhatnagar B
Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32722092
[TBL] [Abstract][Full Text] [Related]
18. Central Nervous System Involvement at the Time of Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with a Poor Outcome in Patients with Acute Myeloid Leukemia.
Ikegawa S; Doki N; Kaito S; Kurosawa S; Sakaguchi M; Harada K; Yamamoto K; Hino Y; Shingai N; Senoo Y; Watanabe D; Hagino T; Yoshioka K; Watakabe K; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
Pathol Oncol Res; 2017 Apr; 23(2):433-437. PubMed ID: 28004352
[TBL] [Abstract][Full Text] [Related]
19. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
[TBL] [Abstract][Full Text] [Related]
20. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.
Chiche E; Rahmé R; Bertoli S; Dumas PY; Micol JB; Hicheri Y; Pasquier F; Peterlin P; Chevallier P; Thomas X; Loschi M; Genthon A; Legrand O; Mohty M; Raffoux E; Auberger P; Caulier A; Joris M; Bonmati C; Roth-Guepin G; Lejeune C; Pigneux A; Vey N; Recher C; Ades L; Cluzeau T
Blood Adv; 2021 Jan; 5(1):176-184. PubMed ID: 33570629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
